Recruiting

Observational Study

Sponsor:

Centre hospitalier de l'Université de Montréal (CHUM)

Code:

NCT06965049

Conditions

Pregnancy

Prematurity

PPROM

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Probiotic

Placebo

Study Details

Brief summary:

The goal of this clinical trial is to evaluate the feasibility of the randomized controlled trial (RCT).

Secondary objectives include comparing the microbiota of preterm babies born after premature rupture of membranes across study groups.

To achieve this, participants will be asked to:

  • Use the vaginal study product from the time of membrane rupture until delivery
  • Keep a diary documenting their symptoms and treatment adherence
  • Provide vaginal secretion samples and stool samples from their baby

Conditions

Pregnancy

Prematurity

PPROM

Study ID

NCT06965049

Start date

Dec 1, 2026

Status verified date

Nov, 2026

Completion date

Sep 29, 2028

Anticipated

Primary completion date

Dec 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • women ≥ 18 years of age;
  • mono-fetal pregnancy;
  • treated for PPROM between 24 and 32 weeks of gestation with latency period between 12 hours and < 7 days in one of the study centers with expectant management;
  • speaking and able to read French or English.

Exclusion Criteria:

  • Presence of active labor;
  • Situation contraindicating expectant management (e.g., infection);
  • Significant malformation, chromosomal anomaly, or fetal death;
  • Signs of fetal distress;
  • Allergy or intolerance to any of the following substances: vitamin C (ascorbic acid), magnesium stearate, maltodextrin, gelatin, yeast, sucrose, trehalose;
  • Allergy to soy or lactose;
  • Weakened immune system (e.g., AIDS, prolonged corticosteroid treatment, etc.);
  • Vaginal probiotics intake 15 days before study inclusion;
  • Oral probiotic intake 30 days before study inclusion.

Study Design

Enrollment

80 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: Probiotics group

Probiotics is a mix of probiotic strains.

placebo comparator: Placebo group

Capsule of sugar, same appearance than the probiotic.

Interventions

Probiotic

Participant will take 1 intravaginal capsule once a day at bedtime between inclusion in the study until delivery

Placebo

Participant will take 1 intravaginal capsule once a day at bedtime between inclusion in the study until delivery

Primary outcome measure

  • Recruitment rate [ Time Frame: 7 months ]
  • Feasability dashboard [ Time Frame: 7 months ]
  • Treatment adherence [ Time Frame: 7 months ]

Central Contacts and Locations

Locations

Centre hospitalier universitaire Sainte-Justine

Recruiting

Montreal, Quebec, Canada, H3T1C5

Contacts

Principal Investigator:

Isabelle Boucoiran

More Information

Sponsor

Centre hospitalier de l'Université de Montréal (CHUM)

Last update posted

Nov 18, 2026

Last verified

Nov, 2026

Keywords

  • pregnancy
  • prematurity
  • PPROM
  • vaginal probiotics
  • microbiota

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by Centre hospitalier de l'Université de Montréal (CHUM) on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.